Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
antineoplastic agents
hormonal
hypogonadism
prostate cancer
testosterone
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
11
2022
accepted:
19
12
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Introduction Many men receiving temporary androgen deprivation therapy (ADT) for localized prostate cancer fail to achieve baseline testosterone levels after cessation. Testosterone recovery in men with localized prostate cancer receiving temporary ADT was assessed. Methods A global federated health research network (TriNetX) was used to identify men diagnosed with prostate cancer undergoing temporary ADT. Two cohorts were identified: men receiving luteinizing hormone-releasing hormone (LHRH) antagonists or LHRH agonists, and men receiving combined ADT (LHRH agonist and antiandrogens). Further stratification was based on a treatment duration of six months (short-term) or 18 months (long-term) to compare testosterone (T) recovery profiles five years after ADT cessation. Results A total of 28,583 men received LHRH agonist or antagonist therapy alone, and 20,188 men received combination ADT. A total of 46.7% of men who received short-term LHRH agonists or antagonists and 40.6% of men who received short-term combined ADT, recovered to mean baseline T levels at five years. Only men who received short-term LHRH agonists/antagonists recovered to eugonadal levels at the five-year follow-up. Around 50% of men who received long-term LHRH agonist/antagonist therapy and 10.7% of men who received combined ADT, recovered to mean baseline T levels at five years. However, neither group recovered to eugonadal T levels. Conclusions At the five-year follow-up after ADT cessation, most patients failed to recover to their mean baseline and eugonadal T levels. Given that testosterone deficiency is associated with metabolically adverse changes in body composition, increased insulin resistance, impaired bone health, and hypogonadal symptoms, serum T levels must be closely monitored in men receiving ADT following treatment cessation.
Identifiants
pubmed: 36686106
doi: 10.7759/cureus.32699
pmc: PMC9848702
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e32699Informations de copyright
Copyright © 2022, Delgado et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Semin Oncol. 2017 Oct;44(5):347-357
pubmed: 29580436
J Urol. 2012 Jun;187(6):2162-6
pubmed: 22503022
Investig Clin Urol. 2018 Jan;59(1):18-24
pubmed: 29333510
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38
pubmed: 30131604
J Urol. 2016 Oct;196(4):1082-9
pubmed: 27131465
Prostate. 2006 Mar 1;66(4):439-44
pubmed: 16329145
Transl Androl Urol. 2018 Jun;7(3):378-389
pubmed: 30050798
Ophthalmic Res. 2022 Oct 13;:
pubmed: 36228576
J Urol. 2018 Aug;200(2):423-432
pubmed: 29601923
Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):834-842
pubmed: 30419308
Asia Pac J Clin Oncol. 2019 Jun;15(3):108-120
pubmed: 30729683
J Sex Med. 2019 Jun;16(6):872-879
pubmed: 31080102
JAMA. 2018 Mar 6;319(9):896-905
pubmed: 29509865
World J Radiol. 2015 Dec 28;7(12):494-500
pubmed: 26753064